Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
28 sept. 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
21 sept. 2023 09h00 HE
|
Krystal Biotech, Inc.
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company...
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
07 sept. 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
05 sept. 2023 07h00 HE
|
Krystal Biotech, Inc.
KB408 IND filed on August 15, 2023 PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the...
Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
21 août 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and...
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
07 août 2023 07h00 HE
|
Krystal Biotech, Inc.
• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa • 121 Patient Start Forms in the first six weeks of launch ...
Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707
26 juil. 2023 16h14 HE
|
Krystal Biotech, Inc.
PITTSBURGH, July 26, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
03 juil. 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, July 03, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech to Present at Upcoming Investor Conferences
05 juin 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, June 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech Announces $160 Million Private Placement Equity Financing
22 mai 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with...